We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App

Breakthrough Blood Test Developed For Schizophrenia Predicts Most Effective Treatments

By LabMedica International staff writers
Posted on 12 Feb 2024
Print article
Image: A new blood test predicts psychosis risk and the most effective treatments (Photo courtesy of 123RF)
Image: A new blood test predicts psychosis risk and the most effective treatments (Photo courtesy of 123RF)

Millions of people worldwide are affected by psychotic disorders, with psychosis typically emerging in young adulthood — a crucial phase of life. Stress and substance use, including marijuana, can trigger psychosis in individuals with a genetic predisposition. Without intervention, psychosis can lead to escalating biological, social, and psychological harm. Schizophrenia, a psychiatric condition characterized by hallucinations and delusions, is challenging to diagnose, particularly in its early stages. It is crucial to match individuals with the most effective treatment from the outset. Now, a new test developed for schizophrenia is capable of identifying biomarkers in a person's blood. This test objectively evaluates their current severity and future risk for the disorder and aligns them with treatments that are most suitable for their unique biological makeup.

In a study, a team of researchers led by Indiana University School of Medicine (Indianapolis, IN, USA) observed psychiatric patients for over a decade. The team identified biomarkers indicative of high hallucination and delusion states, as well as those predictive of future psychiatric hospitalizations related to these symptoms. They also determined which biomarkers are affected by existing drugs, facilitating the alignment of patients with appropriate treatments. This research builds upon two decades of work by the team on blood biomarkers for various psychiatric conditions, including mood disorders, anxiety, post-traumatic stress disorder, suicidality risk, pain, and memory disorders. Notably, the identified biomarkers were found to be more predictive than standard evaluation scales for hallucinations and delusions. This implies that the biomarker test can help minimize subjectivity and uncertainty in psychiatric assessments. The test is expected to be commercially available later this year.

Related Links:
Indiana University School of Medicine

Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Dengue Virus Test

Print article


Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more


view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more


view channel
Image: The Simplexa C. auris direct kit is a real-time polymerase chain reaction assay run on the LIAISON MDX instrument (Photo courtesy of Diasorin)

Novel Molecular Test to Help Prevent and Control Multi Drug-Resistant Fungal Pathogen in Healthcare Settings

Candida auris (C. auris) is a rapidly emerging multi drug-resistant fungal pathogen that is commonly found in healthcare environments, where it presents a challenge due to its ability to asymptomatically... Read more


view channel
Image: The tool can improve precision oncology by accurately predicting molecular subtypes and therapy responses (Photo courtesy of Shutterstock)

Computational Tool Integrates Transcriptomic Data for Improved Breast Cancer Diagnosis and Treatment

Breast cancer is the most commonly diagnosed cancer globally, presenting in various subtypes that require precise identification for effective, personalized treatment. Traditionally, cancer subtyping has... Read more


view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.